(Reuters) -Novo Nordisk has cut its cell therapy division, where it was trying to find a cure for type 1 diabetes, Bloomberg News reported on Friday.

It also cited Danish newspaper Borsen, which reported that the company would lay off nearly all of the unit’s 250 employees.

Novo was testing its cell therapy to generate insulin-producing beta cells for patients with type 1 diabetes in a preclinical study, along with another cell therapy candidate for Parkinson’s disease in early-stage trials.

The latest move is part of CEO Mike Doustdar’s plan to reduce headcount by 11% and reallocate resources to high-priority research areas, the Bloomberg report said.

Novo did not immediately respond to a Reuters request for comment.

The Danish drugmaker is seeking partners to continue developing its

See Full Page